معرفی
Erik Stomrud is an active researcher at Lund University's Faculty of Medicine, Department of Clinical Sciences, holding a dual PhD and MD qualification. He serves as a Clinical Memory Research Researcher and is affiliated with MultiPark, a multidisciplinary research initiative focused on Parkinson's disease. As a Profile Area member of LU's Proactive Ageing initiative, his work contributes to UN Sustainable Development Goals related to health and well-being.
Dr. Stomrud's research primarily focuses on Alzheimer's disease biomarkers, with significant contributions to understanding tau pathology, amyloid-beta interactions, and diagnostic methodologies. His expertise spans cerebrospinal fluid analysis, PET and MRI neuroimaging, and blood-based biomarker development. He specializes in preclinical Alzheimer's disease detection and the relationship between various biomarkers and cognitive decline in neurodegenerative disorders.
Analysis of his recent publications reveals a strong trend toward developing practical diagnostic tools for clinical settings, particularly blood-based biomarkers that can reduce reliance on more invasive or expensive procedures like PET scans. His work increasingly incorporates machine learning approaches to integrate multiple data sources for improved diagnostic accuracy in Alzheimer's disease. The research shows a progression from basic biomarker discovery toward clinical implementation and workflow optimization.
Dr. Stomrud actively supervises research through his role as Assistant Supervisor on the project 'Associations between brain pathologies, regional atrophy, and cognition in Alzheimer's disease and other neurodegenerative disorders.' He serves as Principal Investigator for the 'Utvärdering av substanser för Alzheimer drug discovery' project and contributes as a Researcher to multiple major initiatives including the Swedish BioFINDER study and the EDAP project focused on early diagnostics of Alzheimer's disease. His research receives funding from diverse sources including Hjärnfonden, European Commission FP7, Alzheimerfonden, MultiPark, and The Royal Physiographic Society in Lund.
His laboratory work is centered around the Swedish BioFINDER study, a long-term research initiative running from 2010 to 2027 that investigates biomarkers for neurodegenerative diseases. As part of MultiPark, he collaborates with multidisciplinary teams focused on Parkinson's disease research, demonstrating his cross-disease expertise in neurodegenerative conditions. His current projects indicate ongoing work toward developing more accessible diagnostic tools for memory clinics and advancing our understanding of the complex relationships between different pathological processes in Alzheimer's disease.
